The article presents the results of a comparative analysis of different therapy regimens impact on the effectiveness of treatment of patients with early and late rheumatoid arthritis in steady-state. Data on ongoing basis anti-inflammatory therapy of rheumatoid arthritis and the treatment of associated conditions were obtained by continuous copying from case histories of hospital department patients. The observations lasted 12 months. The activity of rheumatoid arthritis before and after the treatment was determined by the DAS 28 (Disease Activity Score) index. The treatment results were evaluated as per the laboratory research and the DAS 28 index, including the counting of painful and swollen joints, erythrocyte sedimentation rate, and health assessment of the patient on a visual analogue scale.
Keywords: Disease-modifying anti-rheumatic drugs; Rheumatoid arthritis; Treatment; genetically engineered biological drugs; treatment expenses.
Copyright: © 2019 Olga V. Pashanova, Natalia B. Lopatina, Sergey A. Krivosheev, Natalia Y. Baranova.